Shingles Vaccine Market Report 2026

Shingles Vaccine Market Overview

• Shingles Vaccine market size has reached to $5.55 billion in 2025 • Expected to grow to $10.96 billion in 2030 at a compound annual growth rate (CAGR) of 14.5% • Growth Driver: Increasing Number Of Vaccination Programs Fueling The Growth Of The Market Due To Rising Public Awareness And Improved Accessibility • Market Trend: Innovative Recombinant Adjuvanted Vaccines Enhance Shingles Protection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the shingles vaccine market include: • Recombinant Vaccine (Segmentation By Vaccine Type) → Expected gain of $4 Billion • Live Attenuated Vaccine (Segmentation By Vaccine Type) → Expected gain of $0.7 Billion • Subunit Vaccine (Segmentation By Vaccine Type) → Expected gain of $0.5 Billion

What Is Covered Under Shingles Vaccine Market?

Shingles vaccine is a preventive immunization designed to protect against shingles (herpes zoster), a painful skin rash caused by the reactivation of the varicella-zoster virus. It works by stimulating the immune system to recognize and fight against the varicella-zoster virus and helps reduce the risk of developing shingles and its associated complications. The main types of shingles vaccines are live attenuated vaccines, recombinant vaccines, and subunit vaccines, A live attenuated vaccine is a type of vaccine that uses a weakened form of a live pathogen capable of replicating without causing disease to stimulate a strong and lasting immune response. The products types of these vaccines include shingrix, zostavax, and skyzoster and are primarily administered to age groups of 50-59 years, 60-69 years, and 70 years and above. These are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies and cater to various end users such as hospitals, clinics, and pharmacies.

What Is The Shingles Vaccine Market Growth Forecast?

The shingles vaccine market size is expected to see rapid growth in the next few years. It will grow to $10.96 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to development of recombinant and subunit vaccines, expansion of public and private vaccination campaigns, increasing adoption of online and retail pharmacy distribution, rising government and healthcare initiatives for elderly immunization, integration of digital health monitoring for vaccination adherence. Major trends in the forecast period include rising adoption of recombinant and subunit shingles vaccines, increasing awareness of shingles prevention among older adults, expansion of vaccination programs through hospital and retail pharmacies, growth in online pharmacies and e-commerce vaccine distribution, focus on age-specific immunization strategies for 50+ population.

What Is The Driver Of The Shingles Vaccine Market?

The increasing number of vaccination programs is expected to propel the growth of the shingles vaccine market going forward. Vaccination programs refer to organized public health initiatives designed to systematically administer vaccines to populations in order to prevent the spread of infectious diseases. The number of vaccination programs is increasing due to rising awareness about preventive healthcare, encouraging more people to get vaccinated to avoid diseases. Vaccination programs enhance shingles vaccine adoption by increasing public awareness and accessibility, making them ideal for older adults and high-risk populations. They reduce the risk of shingles and related complications by promoting timely and widespread immunization, improving overall community health. For instance, in July 2025, according to the World Health Organization, a Switzerland-based Intergovernmental organization, the coverage for the first dose of human papillomavirus (HPV) vaccine in girls increased from 27% in 2023 to 31% in 2024. Therefore, the increasing number of vaccination programs is driving the growth of the shingles vaccine industry.

How Will The Drivers Impact Growth In The Global Shingles Vaccine Market?

• Rising Aging Population And Disease Burden (Medium) – During the forecast period, the rising aging population and disease burden is expected to become a key growth driver for the shingles vaccine market by 2030. The rising aging population is significantly driving the shingles vaccine market, as older individuals are more susceptible to herpes zoster due to declining immune function. As life expectancy increases globally, the number of people at risk of shingles and its complications continues to grow. This creates sustained demand for preventive vaccination, particularly among individuals aged 50 and above. Healthcare providers are increasingly recommending routine immunization for this age group, boosting vaccine adoption rates. The higher incidence of severe complications such as post-herpetic neuralgia further reinforces the need for vaccination. This growing patient pool drives demand not only for vaccine doses but also for delivery devices and storage solutions. Consequently, it expands the market by increasing consistent and long-term vaccine consumption. • Increasing Awareness Of Vaccination And Preventive Healthcare (High) – During the forecast period, the increasing awareness of vaccination and preventive healthcare is expected to emerge as a major factor driving the expansion of the shingles vaccine market by 2030. Educational campaigns by healthcare organizations and governments are informing individuals about the risks associated with shingles and the benefits of early immunization. This improved awareness reduces vaccine hesitancy and promotes higher acceptance rates among adults. As more people recognize vaccination as a preventive measure rather than a reactive treatment, demand for shingles vaccines rises steadily. Healthcare providers are also actively recommending vaccines during routine check-ups, further boosting uptake. This shift toward prevention increases the need for efficient vaccine delivery systems and infrastructure. Consequently, it expands the market by driving higher adoption across diverse population groups. • Expansion Of Immunization Programs And Healthcare Infrastructure (Low) – During the forecast period, the expansion of immunization programs and healthcare infrastructure is expected to act as a key growth catalyst for the shingles vaccine market by 2030. The expansion of immunization programs and healthcare infrastructure is driving the shingles vaccine market by improving accessibility and distribution efficiency. Governments and health organizations are increasingly incorporating adult vaccination programs into public health strategies, targeting high-risk populations. These initiatives ensure a steady supply and administration of vaccines across hospitals, clinics, and pharmacies. Enhanced healthcare infrastructure supports better storage, transportation, and handling of vaccines through advanced cold chain systems. Increased funding and policy support further strengthen vaccine availability and affordability. As healthcare services expand into rural and underserved regions, more individuals gain access to immunization. Consequently, it expands the market by increasing coverage, accessibility, and overall vaccination rates.

How Will The Restraints Impact Growth In The Global Shingles Vaccine Market?

• High Cost Of Vaccines And Limited Affordability (Medium) – During the forecast period, the the high cost of shingles vaccines acts as a major restraint on market growth by limiting accessibility, especially in low- and middle-income regions. Recombinant vaccines, which are more effective, often require multiple doses, further increasing the overall cost burden for patients. In many countries, inadequate insurance coverage or reimbursement policies restrict widespread adoption. This financial barrier discourages individuals from opting for preventive vaccination despite awareness of its benefits. Healthcare systems with constrained budgets also face challenges in incorporating shingles vaccines into national immunization programs. As a result, demand remains uneven across regions, particularly in price-sensitive markets. Consequently, it restricts the market by reducing vaccination uptake and limiting penetration. • Cold Chain Requirements And Distribution Complexity (High) – During the forecast period, the cold chain requirements and complex distribution logistics significantly restrain the shingles vaccine market by increasing operational challenges. These vaccines require strict temperature-controlled environments during storage and transportation to maintain efficacy. Inadequate infrastructure, particularly in rural or underdeveloped regions, leads to difficulties in maintaining consistent conditions. This increases the risk of vaccine spoilage, wastage, and supply disruptions. Additionally, the need for specialized storage equipment and monitoring systems raises overall distribution costs. Healthcare providers in resource-limited settings may struggle to implement such systems effectively. Consequently, it restricts the market by limiting availability and accessibility of vaccines across diverse geographies. • Vaccine Hesitancy And Low Awareness In Certain Regions (Low) – During the forecast period, the vaccine hesitancy and low awareness act as key restraints by reducing acceptance and adoption of shingles vaccines among target populations. Misinformation regarding vaccine safety and side effects often discourages individuals from getting vaccinated. In many developing regions, limited public health education results in a lack of understanding about shingles severity and prevention. Cultural beliefs and low perceived risk of the disease further contribute to delayed or avoided vaccination. Even where vaccines are available, inconsistent recommendations from healthcare providers can impact uptake rates. This leads to suboptimal vaccination coverage despite strong clinical evidence supporting efficacy. Consequently, it restricts the market by lowering demand and slowing overall growth potential.

Key Players In The Global Shingles Vaccine Market

Major companies operating in the shingles vaccine market are Merck & Co. Inc., GSK plc, SK bioscience, Pfizer Inc, GeneOne Life Science, Curevo Inc, Novavax Inc

Global Shingles Vaccine Market Trends and Insights

Major companies operating in the shingles vaccine market are focusing on developing innovative vaccine formulations, such as recombinant adjuvanted vaccines, to enhance immune response and provide long-lasting protection against shingles. Recombinant adjuvanted vaccines use lab-made viral proteins combined with substances called adjuvants to boost the body's immune response for better and longer-lasting protection. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Shingrix, a shingles vaccine. Shingrix is a non-live, recombinant adjuvanted subunit vaccine administered intramuscularly in two doses for adults aged 50 and above, designed to prevent shingles (herpes zoster) and its related complication, post-herpetic neuralgia. This highly effective vaccine provides over 90% protection against shingles, with strong and sustained immunity lasting at least 10 years, even in older adults and immunocompromised individuals.

What Are Latest Mergers And Acquisitions In The Shingles Vaccine Market?

In October 2023, GSK plc, a UK-based healthcare technology company, partnered with Chongqing Zhifei Biological Products Co. Ltd. to establish an exclusive vaccine distribution and co-promotion agreement in China. With this partnership, GSK and Zhifei aim to significantly expand access to GSK’s shingles vaccine (Shingrix) across over 30,000 vaccination points in China while building a long-term foundation to potentially co-develop and commercialize GSK’s RSV vaccine (Arexvy) for older adults in the Chinese market. Chongqing Zhifei Biological Products Co. Ltd. is a China-based biotechnology company that specializes in the development, manufacture, and distribution of innovative vaccines.

What Defines the Shingles Vaccine Market?

The shingles vaccine market consists of sales of vaccine kits, cold chain storage equipment, pre-filled syringes, vaccine delivery devices, and temperature monitoring systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Shingles Vaccine Market Report 2026?

The shingles vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the shingles vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.